Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
spevatamig + paclitaxel
- Development stage
- Unknown
- Lead developer
- Phanes Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Spevatamig + paclitaxel** is a combination therapy under investigation for advanced solid tumors, including gastric, gastroesophageal junction, pancreatic ductal, and biliary tract carcinomas. Spevatamig (PT886) is a novel investigational biologic agent, and when combined with paclitaxel, a microtubule-stabilizing chemotherapeutic, the two drugs aim to target cancer through complementary mechanisms: Spevatamig by modulating immune or molecular pathways, and paclitaxel by disrupting mitosis and inducing apoptosis in dividing cancer cells. Clinical trials are ongoing to evaluate safety, tolerability, and preliminary efficacy, with initial dosing and safety data now emerging in advanced biliary tract and potentially other gastrointestinal cancers[3][5][7].
- Other names
- spevatamig + paclitaxel
02
Targets
Claudin 18.2CD47 (Cluster of Differentiation 47)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on spevatamig + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on spevatamig + paclitaxel.